Application
Western blot analysis of extracts from HT29 cells untreated or treated with Anisomycin using BRCA1(Phospho-Ser1423) AntibodyApplication
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using BRCA1 (Phospho-Ser1423) Antibody (left) or the same antibody preincubated with blocking peptide (right).Application
Western blot analysis of extracts from HT29 cells untreated or treated with Anisomycin using BRCA1 (Phospho-Ser1423) Antibody .| Product Name | BRCA1 (phospho Ser1423) antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit Polyclonal antibody to BRCA1 (Phospho Ser1423)The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Plays a central role in DNA repair by facilitating cellular response to DNA repair. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation |
| Immunogen | Peptide sequence around phosphorylation site of serine 1423 (H-G-S(p)-Q-P) derived from Human BRCA1. |
| Modification | p-Ser1423 |
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Tested Applications | IHC-PWB |
| Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml (Please refer to the vial label for the specific concentration) |
| Purification | Affinity purified |
| Gene Synonyms | BRCAI BRCC1 BROVCA1 IRIS PNCA4 PSCP RNF53 BRCA1 breast cancer type 1 susceptibility protein RING finger protein 53 breast and ovarian cancer sususceptibility protein 1 breast and ovarian cancer susceptibility protein 1 protein phosphatase 1 re |
|---|---|
| Target | BRCA1 (Phospho Ser1423) |
| Molecular Weight(MW) | 220 (note) |
Application
Western blot analysis of extracts from HT29 cells untreated or treated with Anisomycin using BRCA1(Phospho-Ser1423) Antibody
Application
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using BRCA1 (Phospho-Ser1423) Antibody (left) or the same antibody preincubated with blocking peptide (right).
Application
Western blot analysis of extracts from HT29 cells untreated or treated with Anisomycin using BRCA1 (Phospho-Ser1423) Antibody .| Application Notes | Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
